使用粗针穿刺活检的MammaPrint指导乳腺手术中腋窝分期需求
本研究回顾单机构2020至2021年668例cT1-2N0雌激素受体阳性/人表皮生长因子受体2阴性浸润性乳腺癌患者,比较MammaPrint风险与病理淋巴结状态。低风险luminal A型481例(72%),高风险luminal B型187例(28%);低风险MammaPrint与病理淋巴结阳性风险无显著关联(P=0.377)。结论认为低风险MammaPrint不能预测病理淋巴结阴性,基因组检测似乎不能为Choosing Wisely指南之外的患者省略前哨淋巴结活检提供额外个体化依据。
要点
- 668例cT1-2N0雌激素受体阳性/HER2阴性乳腺癌中,MammaPrint低风险luminal A型481例(72%),高风险luminal B型187例(28%)。
- 病理淋巴结阴性与阳性队列中多数均为低风险MammaPrint(355例[73.3%] vs 91例[69.5%]),低风险MammaPrint未显著降低病理淋巴结阳性风险(P=0.377)。
- 作者认为基因组检测似乎不能为Choosing Wisely指南之外的患者省略前哨淋巴结活检提供额外个体化依据。
核心结论
- 低风险MammaPrint不能预测病理淋巴结阴性乳腺癌的较低风险。
- 基于本研究结果,基因组检测似乎不能为Choosing Wisely指南之外的患者省略前哨淋巴结活检提供额外个体化依据。
研究设计与样本
- 单机构数据库查询,纳入2020至2021年以乳腺手术为首个治疗且完成MammaPrint检测的cT1-2N0雌激素受体阳性/人表皮生长因子受体2阴性浸润性乳腺癌女性。
- 共668例女性符合纳入标准,中位年龄66岁。
主要发现
- MammaPrint低风险luminal A型481例(72%),高风险luminal B型187例(28%)。
- 乳腺手术时,588例(88%)接受前哨淋巴结活检,27例(4%)接受腋窝淋巴结清扫,53例(7.9%)未行腋窝分期。
- 病理淋巴结阴性与阳性队列中多数均为低风险MammaPrint(355例[73.3%] vs 91例[69.5%])。
- 低风险MammaPrint女性的病理淋巴结阳性风险未显著降低(P=0.377)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: At present, the only opportunity to omit axillary staging is with Choosing Wisely criteria for women ages >70 y with cT1 2N0 estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. However, many women are diagnosed when pathologic node status-negative, raising the question of additional opportunities to omit sentinel lymph node biopsy. We sought to investigate the association between MammaPrint, a genomic test that estimates estrogen receptor-positive breast cancer recurrence risk, and pathologic node status, with the aim that low-risk MammaPrint could be considered for omission of sentinel lymph node biopsy if associated with pathologic node status-negative. METHODS: A single-institution database was queried for all women with cT1 2N0 estrogen receptor-positive/human epidermal growth factor receptor 2-negative invasive breast cancer with breast surgery as their first treatment and MammaPrint performed from 2020 to 2021. Patient and tumor factors, including MammaPrint score, were compared with axillary node status for correlation. RESULTS: A total of 668 women met inclusion criteria, with a median age of 66 y. MammaPrint was low-risk luminal A in 481 (72%) and high-risk luminal B in 187 (28%). At the time of breast surgery, 588 (88%) had sentinel lymph node biopsy, 27 (4%) had axillary lymph node dissection, and 53 (7.9%) had no axillary staging. Most women in both the pathologic node status-negative and pathologic node status-positive cohorts had low-risk MammaPrint (355 [73.3%] pathologic node status-negative vs 91 [69.5%] pathologic node status-positive), and women with low-risk MammaPrint did not have a significantly lower risk of pathologic node status-positive (P = .377). CONCLUSION: Low-risk MammaPrint does not predict lower risk of pathologic node status-positive breast cancer. Based on our results, genomic testing does not appear to provide additional personalization for the ability to omit sentinel lymph node biopsy for patients outside of the Choosing Wisely guidelines.
引用
- Drapalik LM, Miller ME, Rock L, et al. Using MammaPrint on core needle biopsy to guide the need for axillary staging during breast surgery. Surgery. 2023. PMID: 37852835. doi:10.1016/j.surg.2023.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。